Rani Therapeutics Holdings (RANI) Income from Continuing Operations (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Income from Continuing Operations of 10354000.0 for Q1 2026, up 18.72% year-over-year from 8721680.47 in Q1 2025, and down 20.02% quarter-over-quarter from 8627000.0 in Q4 2025.
Rani Therapeutics Holdings (RANI) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 10354000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 18.72% year-over-year to 10354000.0; the TTM figure through Mar 2026 stood at 42236000.0 (up 25.13% YoY), while the FY2025 annual figure was 116540000.0, down 105.96% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 10354000.0, down from 8627000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 8627000.0 in Q4 2025, with the low at 18664000.0 in Q2 2023.
- The 5-year median for Income from Continuing Operations is 14055000.0 (2023), against an average of 14393411.76.
- Peak annual rise in Income from Continuing Operations reached 43.52% in 2022, while the deepest fall reached 191.08% in 2022.
- Rani Therapeutics Holdings' Income from Continuing Operations stood at 17372000.0 in 2022, then grew by 19.09% to 14055000.0 in 2023, then gained by 13.42% to 12169000.0 in 2024, then rose by 29.11% to 8627000.0 in 2025, then retreated by 20.02% to 10354000.0 in 2026.
- Business Quant data shows RANI's Income from Continuing Operations at 10354000.0 in Q1 2026, 8627000.0 in Q4 2025, and 11959000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Rani Therapeutics Holdings | 163.98 Mn | 163.98 Mn | - | -8.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.46 Mn |
| Mar 31, 2026 | -10.35 Mn |
| Dec 31, 2025 | -8.63 Mn |
| Sep 30, 2025 | -11.96 Mn |
| Jun 30, 2025 | -11.30 Mn |
| Mar 31, 2025 | -12.74 Mn |
| Dec 31, 2024 | -12.17 Mn |
| Sep 30, 2024 | -18.05 Mn |
| Jun 30, 2024 | -13.46 Mn |
| Mar 31, 2024 | -14.78 Mn |
| Dec 31, 2023 | -14.06 Mn |
| Sep 30, 2023 | -18.33 Mn |
| Jun 30, 2023 | -18.66 Mn |
| Mar 31, 2023 | -16.83 Mn |
| Dec 31, 2022 | -17.37 Mn |
| Sep 30, 2022 | -16.21 Mn |
| Jun 30, 2022 | -15.97 Mn |
| Mar 31, 2022 | -13.83 Mn |
| Dec 31, 2021 | -13.31 Mn |
| Sep 30, 2021 | -28.70 Mn |